Nicholas J. Veomett, Ph.D.
Affiliations: | 2014 | Weill Cornell Medical College, New York, NY, United States |
Area:
Pharmacology, Oncology, ImmunologyGoogle:
"Nicholas Veomett"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| David A. Scheinberg | grad student | 2014 | Weill Cornell Medical College | |
| (Regulating the therapeutic efficacy of a TCR-like antibody to intracellular WT1 via FC engineering and target modulation.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Dao T, Pankov D, Scott A, et al. (2015) Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nature Biotechnology |
| Veomett N, Dao T, Liu H, et al. (2014) Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4036-46 |
| Veomett N, Dao T, Scheinberg DA. (2013) Therapeutic antibodies to intracellular targets in cancer therapy. Expert Opinion On Biological Therapy. 13: 1485-8 |
| Mallikaratchy P, Gardner J, Nordstrøm LU, et al. (2013) A self-assembling short oligonucleotide duplex suitable for pretargeting. Nucleic Acid Therapeutics. 23: 289-99 |
| Dao T, Yan S, Veomett N, et al. (2013) Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Science Translational Medicine. 5: 176ra33 |
| Dubrovsky L, Brea EJ, Veomett NJ, et al. (2013) Therapeutic superiority of a TCR-like antibody to an intracellular WT1 oncogene peptide compared with the tyrosine kinase inhibitor imatinib in a mouse model of Philadelphia chromosome positive (Ph+) ALL. Journal of Clinical Oncology. 31: 3047-3047 |
| Dubrovsky L, Brea E, Pankov D, et al. (2013) Therapeutic Efficacy and Cure Of Sensitive and T315I Pan-Resistant Human Ph+ Leukemia In Mice Using a TCR-Like Antibody To WT1/HLA-A0201 Alone, Or In Combination With Tyrosine Kinase Inhibitors Blood. 122: 855-855 |
| Pankov D, Dao T, Wang Y, et al. (2013) A Bi-Specific T Cell Engaging Monoclonal Antibody (mAb) Derived From a TCR-Like Mab Specific For WT1/HLA-A0201 (ESK-BiTE) Shows a Potent Activity Against Human AML and Ph+ ALL In Mouse Models Blood. 122: 2521-2521 |
| Tseng HM, Shum D, Bhinder B, et al. (2012) A high-throughput scintillation proximity-based assay for human DNA ligase IV. Assay and Drug Development Technologies. 10: 235-49 |
| Veomett N, Dao T, Pankov D, et al. (2012) Native and Fc Enhanced Therapeutic Human Monoclonal Antibodies Targeting the Intracellular WT1 Oncogene Product in Leukemia. Blood. 120: 2599-2599 |